Oncology biotech Monopar Therapeutics sets terms for $40 million IPO
Monopar Therapeutics, a Phase 3 biotech developing therapies for various types of cancer, announced terms for its IPO on Tuesday.
The Wilmette, IL-based company plans to raise $40 million by offering 4.4 million shares at a price range of $8 to $10. At the midpoint of the proposed range, Monopar Therapeutics would command a fully diluted market value of $130 million.
Monopar Therapeutics was founded in 2014 and plans to list on the Nasdaq under the symbol MNPR. JonesTrading is the sole bookrunner on the deal.
The article Oncology biotech Monopar Therapeutics sets terms for $40 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.